Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
881.3 DKK | -0.79% | -2.29% | +26.24% |
12:28pm | Novo Nordisk Asked by Bernie Sanders to Lower List Price of Diabetes, Weight-Loss Drug | MT |
Mar. 27 | Novo Nordisk Asked by Bernie Sanders to Lower List Price of Diabetes, Weight-Loss Drug | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With an expected P/E ratio at 38.12 and 31.29 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+26.24% | 571B | B | ||
+35.33% | 701B | C+ | ||
+1.18% | 381B | C+ | ||
+20.86% | 334B | B- | ||
+17.03% | 319B | C+ | ||
+1.01% | 210B | B+ | ||
+2.75% | 210B | B- | ||
-6.16% | 201B | A+ | ||
-3.18% | 157B | C+ | ||
-0.58% | 153B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Novo Nordisk A/S - Nasdaq Copenhagen
- Ratings Novo Nordisk A/S